Focus Partners Advisor Solutions LLC Lowers Stake in Bristol-Myers Squibb (NYSE:BMY)

Focus Partners Advisor Solutions LLC decreased its position in Bristol-Myers Squibb (NYSE:BMY - Free Report) by 39.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 27,054 shares of the biopharmaceutical company's stock after selling 17,359 shares during the quarter. Focus Partners Advisor Solutions LLC's holdings in Bristol-Myers Squibb were worth $1,530,000 as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in BMY. CSS LLC IL increased its stake in Bristol-Myers Squibb by 19.9% during the fourth quarter. CSS LLC IL now owns 31,940 shares of the biopharmaceutical company's stock worth $1,807,000 after purchasing an additional 5,310 shares during the period. Kolinsky Wealth Management LLC acquired a new position in shares of Bristol-Myers Squibb in the fourth quarter valued at approximately $204,000. Continuum Advisory LLC increased its stake in Bristol-Myers Squibb by 15.1% during the 4th quarter. Continuum Advisory LLC now owns 1,733 shares of the biopharmaceutical company's stock worth $98,000 after buying an additional 227 shares during the period. NCM Capital Management LLC lifted its holdings in Bristol-Myers Squibb by 1.1% during the 4th quarter. NCM Capital Management LLC now owns 21,626 shares of the biopharmaceutical company's stock worth $1,223,000 after buying an additional 238 shares in the last quarter. Finally, Principal Street Partners LLC boosted its position in Bristol-Myers Squibb by 1.7% in the 4th quarter. Principal Street Partners LLC now owns 120,268 shares of the biopharmaceutical company's stock valued at $6,802,000 after buying an additional 2,053 shares during the period. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Bristol-Myers Squibb Trading Down 0.0%

NYSE BMY opened at $46.99 on Friday. Bristol-Myers Squibb has a 12 month low of $39.35 and a 12 month high of $63.33. The company has a market capitalization of $95.63 billion, a price-to-earnings ratio of -10.63, a price-to-earnings-growth ratio of 2.07 and a beta of 0.39. The company has a debt-to-equity ratio of 2.90, a current ratio of 1.25 and a quick ratio of 1.15. The firm's fifty day moving average price is $52.05 and its 200 day moving average price is $55.77.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last posted its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 EPS for the quarter, topping analysts' consensus estimates of $1.50 by $0.30. Bristol-Myers Squibb had a positive return on equity of 13.93% and a negative net margin of 18.53%. The business had revenue of $11.20 billion for the quarter, compared to analysts' expectations of $10.77 billion. During the same quarter in the previous year, the firm earned ($4.40) earnings per share. The business's revenue was down 5.6% compared to the same quarter last year. On average, sell-side analysts expect that Bristol-Myers Squibb will post 6.74 earnings per share for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, May 1st. Stockholders of record on Friday, April 4th were issued a $0.62 dividend. This represents a $2.48 annualized dividend and a dividend yield of 5.28%. The ex-dividend date of this dividend was Friday, April 4th. Bristol-Myers Squibb's payout ratio is currently 92.88%.

Wall Street Analyst Weigh In

BMY has been the topic of a number of recent research reports. Wells Fargo & Company upped their price objective on Bristol-Myers Squibb from $60.00 to $62.00 and gave the stock an "equal weight" rating in a research report on Friday, February 7th. Argus upgraded Bristol-Myers Squibb to a "hold" rating in a report on Friday, April 25th. Citigroup lifted their price objective on Bristol-Myers Squibb from $60.00 to $65.00 and gave the company a "neutral" rating in a research note on Tuesday, January 28th. Cantor Fitzgerald restated a "neutral" rating and set a $55.00 target price on shares of Bristol-Myers Squibb in a research note on Tuesday, April 22nd. Finally, UBS Group decreased their price target on shares of Bristol-Myers Squibb from $60.00 to $54.00 and set a "neutral" rating for the company in a research note on Friday, April 11th. Two analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, five have issued a buy rating and three have issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, Bristol-Myers Squibb has an average rating of "Hold" and a consensus target price of $58.00.

Insider Transactions at Bristol-Myers Squibb

In other Bristol-Myers Squibb news, EVP Samit Hirawat purchased 4,250 shares of Bristol-Myers Squibb stock in a transaction that occurred on Friday, April 25th. The stock was purchased at an average price of $47.58 per share, for a total transaction of $202,215.00. Following the transaction, the executive vice president now directly owns 83,513 shares in the company, valued at $3,973,548.54. This trade represents a 5.36% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 0.07% of the company's stock.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb (NYSE:BMY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.